PBPH
Portfolio Building Block World Pharma And Biotech Index ETF
Price Chart
Latest Quote
$29.98
+0.03 (+0.08%)
Current Price
| Previous Close | $29.95 |
| Open | $29.61 |
| Day High | $29.98 |
| Day Low | $29.61 |
| Volume | 10,052 |
Fund Information
| Net Assets | $1.05B |
| Expense Ratio | 0.13% |
| Category | Health |
| Fund Family | Portfolio Building Block ETFs |
| Net Asset Value | $29.89 |
| Premium/Discount | 0.27% |
| P/E Ratio | 28.63 |
| Exchange | NGM |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $28.87 |
| SMA50 | $28.80 |
| SMA200 | $26.81 |
| RSI | 73.54 |
| ATR | 0.4535 |
| Rel Volume | 0.10 |
Performance History
| Week | +0.93% |
| Month | +4.58% |
| Quarter | +8.88% |
| 6 Months | +23.37% |
| YTD | +18.42% |
| 10 Years | +21.04% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-28 | $29.98 | 10,052 |
| 2026-10-27 | $29.97 | 111,200 |
| 2026-10-26 | $29.85 | 115,000 |
| 2026-10-23 | $29.83 | 137,300 |
| 2026-10-22 | $30.13 | 163,300 |
| 2026-10-21 | $29.70 | 114,400 |
| 2026-10-20 | $29.81 | 113,800 |
| 2026-10-19 | $28.99 | 116,800 |
| 2026-10-16 | $29.15 | 99,100 |
| 2026-10-15 | $29.23 | 125,400 |
| 2026-10-14 | $28.68 | 101,800 |
| 2026-10-13 | $27.92 | 66,700 |
| 2026-10-12 | $28.40 | 90,100 |
| 2026-10-09 | $28.35 | 75,200 |
| 2026-10-08 | $27.97 | 93,800 |
| 2026-10-07 | $28.19 | 110,900 |
| 2026-10-06 | $27.83 | 105,600 |
| 2026-10-05 | $27.75 | 78,100 |
| 2026-10-02 | $27.82 | 81,200 |
| 2026-10-01 | $27.92 | 152,200 |
| 2026-09-30 | $28.39 | 91,100 |
| 2026-09-29 | $28.66 | 95,800 |
| 2026-09-28 | $28.82 | 87,400 |
About Portfolio Building Block World Pharma And Biotech Index ETF
The fund uses a “passive management” approach to track the performance, before fees and expenses, of the index. The index is constructed using a rules-based methodology that identifies companies in the pharmaceutical and/or biotechnology industries with publicly traded ordinary shares listed on major stock exchanges in developed markets, as classified by BITA GmbH. Under normal circumstances, the fund will invest at least 80% of the fund’s net assets in component securities that make up the index. The fund is non-diversified.
📰 Latest News
No news articles available at the moment. Check back later for updates on PBPH.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.